Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms

Nature Reviews Clinical Oncology

Volumn 13, Issue 11, 2016, Pages 691-705

  Kidd, Mark ^a   Modlin, Irvin ^a   Öberg, Kjell ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BEVACIZUMAB; CISPLATIN; CIXUTUMUMAB; DACTOLISIB; DALOTUZUMAB; DOPAMINE 2 RECEPTOR; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; OCTREOTIDE; PANITUMUMAB; PASIREOTIDE; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; SOMATOMEDIN; SOMATOSTATIN RECEPTOR; SORAFENIB; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TUMOR MARKER; TUMOR PROTEIN; VASCULOTROPIN A;

CANCER PROGNOSIS; CANCER RESISTANCE; CARCINOID; CARCINOID SYNDROME; CHROMOSOMAL INSTABILITY; COPY NUMBER VARIATION; CPG ISLAND; DISEASE FREE SURVIVAL; DNA METHYLATION; GASTRINOMA; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GASTROINTESTINAL NEUROENDOCRINE TUMOR; GASTROINTESTINAL TUMOR; GENE EXPRESSION; GENOMIC INSTABILITY; GERMLINE MUTATION; HETEROZYGOSITY LOSS; HUMAN; INTESTINE NEUROENDOCRINE TUMOR; INTESTINE TUMOR; LUNG NEUROENDOCRINE TUMOR; LUNG TUMOR; MICROSATELLITE INSTABILITY; MOLECULAR IMAGING; NEUROENDOCRINE TUMOR; NONHUMAN; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; SMALL INTESTINAL NEUROENDOCRINE TUMOR; SMALL INTESTINE TUMOR; SOMATIC MUTATION; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; CLASSIFICATION; CLINICAL TRIAL (TOPIC); GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; NEOVASCULARIZATION (PATHOLOGY); PANCREAS TUMOR; PHENOTYPE; PHYSIOLOGY; TUMOR GENE;

BIOMARKERS, TUMOR; CLINICAL TRIALS AS TOPIC; DNA METHYLATION; EPIDERMAL GROWTH FACTOR; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; MUTATION; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTORS, SOMATOSTATIN; SIGNAL TRANSDUCTION; SOMATOMEDINS; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84976285439     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2016.85     Document Type: Review

References (169)

1. Modlin, I. M., et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 9, 61-72 (2008
2. Yao, J. C., et al. One hundred years after-carcinoid-: epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. J. Clin. Oncol. 26, 3063-3072 (2008
3. Lawrence, B., et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol. Metab. Clin. North Am. 40, 1-18 (2011
4. De Mestier, L., et al. Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art. Endocr. Relat. Cancer 21, R105-R120 2014.
5. Bergsland, E. K. The evolving landscape of neuroendocrine tumors. Semin. Oncol. 40, 4-22 (2013
6. Modlin, I. M., Moss, S. F., Chung, D. C., Jensen, R. T., & Snyderwine, E. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J. Natl Cancer Inst. 100, 1282-1289 (2008
7. Bosman, F T., & Carneiro, F. WHO Classification of Tumours, Pathology and Genetics of Tumours of the Digestive System (IARC Press 2010
8. McCall, C. M., et al. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate. Am. J. Surg. Pathol. 37, 1671-1677 (2013
9. Reid, M. D., Balci, S., Saka, B., & Adsay, N. V. Neuroendocrine tumors of the pancreas: current concepts and controversies. Endocr. Pathol. 25, 65-79 (2014
10. Velayoudom-Cephise, F. L., et al. Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr. Relat. Cancer 20, 649-657 (2013
11. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012
12. Jass, J. R. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50, 113-130 (2007
13. Domingo, E., et al. Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. J. Pathol. 229, 441-448 (2013
14. Perou, C. M., et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000
15. Schnitt, S. J. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Mod. Pathol 23, S60-S64 2010.
16. Rindi, G., et al. TNM staging of foregut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 449, 395-401 (2006
17. Oberg, K. Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches. Curr. Opin. Oncol. 24, 433-440 (2012
18. Sundin, A. Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours. Best Pract. Res. Clin. Gastroenterol. 26, 803-818 (2012
19. Baum, R. P., Kulkarni, H. R., & Carreras, C. Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms. Semin. Nucl. Med. 42, 190-207 (2012
20. Koopmans, K. P., et al. Staging of carcinoid tumours with 18F DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol. 7, 728-734 (2006
21. Kjaer, A. Molecular imaging of cancer using PET and SPECT. Adv. Exp. Med. Biol. 587, 277-284 (2006
22. Binderup, T., Knigge, U., Loft, A., Federspiel, B., & Kjaer, A. 18F fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin. Cancer Res. 16, 978-985 (2010
23. Bahri, H., et al. High prognostic value of 18F FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation. J. Nucl. Med. 55, 1786-1790 (2014
24. Garin, E., & Edeline, J. Reply: modifying the poor prognosis associated with 18F FDG-avid NET with peptide receptor chemo-radionuclide therapy (PRCRT). J. Nucl. Med. 56, 969 (2015
25. Susini, C., & Buscail, L. Rationale for the use of somatostatin analogs as antitumor agents. Ann. Oncol. 17, 1733-1742 (2006
26. Reubi, J. C. Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 80 (Suppl. 1), 51-56 (2004
27. Bertherat, J., et al. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J. Clin. Endocrinol. Metab. 88, 5353-5360 (2003
28. Mirallie, E., et al. Value of endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localization of insulinomas and gastrinomas. Experience of 54 cases. Gastroenterol. Clin. Biol. 26, 360-366 (in French) (2002
29. Vezzosi, D., et al. Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti sst2A and anti sst5 antibodies. Eur. J. Endocrinol. 152, 757-767 (2005
30. Srirajaskanthan, R., Watkins, J., Marelli, L., Khan, K., & Caplin, M. E. Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies. Neuroendocrinology 89, 308-314 (2009
31. Kvols, L. K., et al. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide. Yale J. Biol. Med. 65, 505-518; discussion 531-536 (1992
32. Rinke, A., et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol. 27, 4656-4663 (2009
33. Caplin, M. E., et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N. Engl. J. Med. 371, 224-233 (2014
34. Kvols, L. K., et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr. Relat. Cancer 19, 657-666 (2012
35. Lebtahi, R., et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J. Nucl. Med. 38, 853-858 (1997
36. Bodei, L., Sundin, A., Kidd, M., Prasad, V., & Modlin, I M. The status of neuroendocrine tumor imaging: from darkness to light- Neuroendocrinology 101 1-17 2015
37. Ruszniewski, P. ECC 2015 press release: rare cancer responds unusually well to new treatment: results from the NETTER 1 trial. ESMO http://www.esmo.org/Conferences/Past-Conferences/European-Cancer- Congress-2015/News/Rare-cancer-responds-unusually-well-to-new-treatment-results-from-the-NETTER-1-trial 2015
38. Okuwaki, K., et al. Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes. Cancer 119, 4094-4102 (2013
39. Pinato, D. J., et al. An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes. Br. J. Cancer 110, 115-122 (2014
40. Campana, D., et al. Standardized uptake values of 68Ga DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J. Nucl. Med. 51, 353-359 (2010
41. Kwekkeboom, D. J., et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr. Relat. Cancer 17, R53-R73 2010
42. Kidd, M., Modlin, I. M., Bodei, L., & Drozdov, I. Decoding the molecular and mutational ambiguities of gastroenteropancreatic neuroendocrine neoplasm pathobiology. Cell. Mol. Gastroenterol. Hepatol. 1, 131-153 (2015
43. Larsson, C., Skogseid, B., Oberg, K., Nakamura, Y., & Nordenskjold, M. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 332, 85-87 (1988
44. Hughes, C. M., et al. Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol. Cell 13, 587-597 (2004
45. Richard, S., et al. Von Hippel-Lindau disease: recent genetic progress and patient management. Francophone Study Group of von Hippel-Lindau Disease (GEFVH). Ann. Endocrinol. (Paris) 59, 452-458 (in French) (1998
46. Ruggieri, M., & Huson, S. M. The neurofibromatoses. An overview. Ital. J. Neurol. Sci. 20, 89-108 (1999
47. Au, K. S., Williams, A. T., Gambello, M. J., & Northrup, H. Molecular genetic basis of tuberous sclerosis complex: from bench to bedside. J. Child Neurol. 19, 699-709 (2004
48. Matkar, S., Thiel, A., & Hua, X. Menin: a scaffold protein that controls gene expression and cell signaling. Trends Biochem. Sci. 38, 394-402 (2013
49. Bluyssen, H. A., et al. Fibronectin is a hypoxia-independent target of the tumor suppressor VHL. FEBS Lett. 556, 137-142 (2004
50. Kibel, A., Iliopoulos, O., DeCaprio, J. A., & Kaelin, W. G. Jr. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 269, 1444-1446 (1995
51. Faggiano, A., et al. Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study. J. Endocrinol. Invest. 35, 817-823 (2012
52. Jiao, Y., et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331, 1199-1203 (2011
53. Langer, P., et al. Prospective evaluation of imaging procedures for the detection of pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. World J. Surg. 28, 1317-1322 (2004
54. Van Asselt, S. J., et al. EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1. Gastrointest. Endosc. 81, 159-167.e2 (2015
55. De Wilde, R. F., et al. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN 1 syndrome pancreatic neuroendocrine tumors. Mod. Pathol. 25, 1033-1039 (2012
56. Corcos, O., et al. Endocrine pancreatic tumors in von Hippel-Lindau disease: clinical, histological, and genetic features. Pancreas 37, 85-93 (2008
57. Sei, Y., et al A Hereditary Form of Small Intestinal Carcinoid Associated with A Germline Mutation in Inositol Polyphosphate Multikinase. Gastroenterology 2015 149 67-78
58. Spurdle, A B., et al. Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Res 16 3419 2014
59. Jonkers, Y. M., et al. Chromosomal instability predicts metastatic disease in patients with insulinomas. Endocr. Relat. Cancer 12, 435-447 (2005
60. Zhuang, Z., et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res. 57, 4682-4686 (1997
61. Cao, Y., et al. Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1. Nat. Commun. 4, 2810 (2013
62. Shay, J. W., Reddel, R. R., & Wright, W. E. Cancer and telomeres- an ALTernative to telomerase. Science 336, 1388-1390 (2012
63. Heaphy, C. M., et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 333, 425 (2011
64. Marinoni, I., et al. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology 146, 453-460.e5 (2014
65. Zhou, C., Dhall, D., Nissen, N. N., Chen, C. R., & Yu, R. Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, a cell hyperplasia, and islet cell tumor. Pancreas 38, 941-946 (2009
66. Lin, W., et al. Dynamic epigenetic regulation by menin during pancreatic islet tumor formation. Mol. Cancer Res. 13, 689-698 (2015
67. Gurung, B., et al. PTCH 1 staining of pancreatic neuroendocrine tumor (PNET) samples from patients with and without multiple endocrine neoplasia (MEN 1) syndrome reveals a potential therapeutic target. Cancer Biol. Ther. 16, 219-224 (2015
68. Banck, M. S., et al. The genomic landscape of small intestine neuroendocrine tumors. J. Clin. Invest. 123, 2502-2508 (2013
69. Francis, J. M., et al. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat. Genet. 45, 1483-1486 (2013
70. Lee, M., & Pellegata, N. S. Multiple endocrine neoplasia syndromes associated with mutation of p27. J. Endocrinol. Invest. 36, 781-787 (2013
71. Kytola, S., et al. Alterations of the SDHD gene locus in midgut carcinoids, Merkel cell carcinomas, pheochromocytomas, and abdominal paragangliomas. Genes Chromosomes Cancer 34, 325-332 (2002
72. Karnik, S. K., et al. Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc. Natl Acad. Sci. USA 102, 14659-14664 (2005
73. Ghimenti, C., Lonobile, A., Campani, D., Bevilacqua, G., & Caligo, M. A. Microsatellite instability and allelic losses in neuroendocrine tumors of the gastro-entero-pancreatic system. Int. J. Oncol. 15, 361-366 (1999
74. Arnold, C. N., Sosnowski, A., & Blum, H. E. Analysis of molecular pathways in neuroendocrine cancers of the gastroenteropancreatic system. Ann. NY Acad. Sci. 1014, 218-219 (2004
75. House, M. G., et al. Prognostic value of hMLH1 methylation and microsatellite instability in pancreatic endocrine neoplasms. Surgery 134, 902-908; discussion 909 (2003
76. Kidd, M., et al. Microsatellite instability and gene mutations in transforming growth factor-beta type II receptor are absent in small bowel carcinoid tumors. Cancer 103, 229-236 (2005
77. Speel, E. J., et al. Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization. Am. J. Pathol. 155, 1787-1794 (1999
78. Speel, E. J., et al. Genetic evidence for early divergence of small functioning and nonfunctioning endocrine pancreatic tumors: gain of 9Q34 is an early event in insulinomas. Cancer Res. 61, 5186-5192 (2001
79. Simon, B., & Lubomierski, N. Implication of the INK4a/ARF locus in gastroenteropancreatic neuroendocrine tumorigenesis. Ann. NY Acad. Sci. 1014, 284-299 (2004
80. Zikusoka, M. N., Kidd, M., Eick, G., Latich, I., & Modlin, I. M. The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer 104, 2292-2309 (2005
81. Perren, A., et al. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am. J. Pathol. 157, 1097-1103 (2000
82. Missiaglia, E., et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J. Clin. Oncol. 28, 245-255 (2010
83. Hu, W., et al. Gene amplifications in well-differentiated pancreatic neuroendocrine tumors inactivate the p53 pathway. Genes Cancer 1, 360-368 (2010
84. Kytola, S., et al. Comparative genomic hybridization identifies loss of 18q22 qter as an early and specific event in tumorigenesis of midgut carcinoids. Am. J. Pathol. 158, 1803-1808 (2001
85. Lollgen, R. M., Hessman, O., Szabo, E., Westin, G., & Akerstrom, G. Chromosome 18 deletions are common events in classical midgut carcinoid tumors. Int. J. Cancer 92, 812-815 (2001
86. Andersson, E., Sward, C., Stenman, G., Ahlman, H., & Nilsson, O. High-resolution genomic profiling reveals gain of chromosome 14 as a predictor of poor outcome in ileal carcinoids. Endocr. Relat. Cancer 16, 953-966 (2009
87. Arnold, C. N., Sosnowski, A., Schmitt-Graff, A., Arnold, R., & Blum, H. E. Analysis of molecular pathways in sporadic neuroendocrine tumors of the gastro-entero-pancreatic system. Int. J. Cancer 120, 2157-2164 (2007
88. Chan, A. O., et al. CpG island methylation in carcinoid and pancreatic endocrine tumors. Oncogene 22, 924-934 (2003
89. House, M. G., et al. Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Ann. Surg. 238, 423-431; discussion 431-432 (2003
90. Kulke, M. H., et al. O6 methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin. Cancer Res. 15, 338-345 (2009
91. Walter, T., et al. O6 methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents. Br. J. Cancer 112, 523-531 (2015
92. Schmitt, A. M., et al. VHL inactivation is an important pathway for the development of malignant sporadic pancreatic endocrine tumors. Endocr. Relat. Cancer 16, 1219-1227 (2009
93. Dejeux, E., et al. Hypermethylation of the IGF2 differentially methylated region 2 is a specific event in insulinomas leading to loss of imprinting and overexpression. Endocr. Relat. Cancer 16, 939-952 (2009
94. Boissan, M., et al. Implication of metastasis suppressor NM23 H1 in maintaining adherens junctions and limiting the invasive potential of human cancer cells. Cancer Res. 70, 7710-7722 (2010
95. Hendy, G. N., Kaji, H., Sowa, H., Lebrun, J. J., & Canaff, L. Menin and TGF-β superfamily member signaling via the Smad pathway in pituitary, parathyroid and osteoblast. Horm. Metab. Res. 37, 375-379 (2005
96. Gurung, B., Feng, Z., & Hua, X. Menin directly represses Gli1 expression independent of canonical Hedgehog signaling. Mol. Cancer Res. 11, 1215-1222 (2013
97. Yang, Y. J., et al. Menin mediates epigenetic regulation via histone H3 lysine 9 methylation. Cell Death Dis. 4, e583 2013
98. Fotouhi, O., et al. Global hypomethylation and promoter methylation in small intestinal neuroendocrine tumors: an in vivo and in vitro study. Epigenetics 9, 987-997 (2014
99. Zhang, H. Y., et al. Association of DNA methylation and epigenetic inactivation of RASSF1A and beta-catenin with metastasis in small bowel carcinoid tumors. Endocrine 30, 299-306 (2006
100. Duerr, E. M., et al. Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis. Endocr. Relat. Cancer 15, 243-256 (2008
101. Dilley, W. G., et al. Global gene expression in neuroendocrine tumors from patients with the MEN1 syndrome. Mol. Cancer 4, 9 (2005
102. Roldo, C., et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J. Clin. Oncol. 24, 4677-4684 (2006
103. Kidd, M., Modlin, I. M., & Drozdov, I. Gene network-based analysis identifies two potential subtypes of small intestinal neuroendocrine tumors. BMC Genomics 15, 595 (2014
104. Kidd, M., et al. The role of genetic markers- NAP1L1, MAGE D2, and MTA1- in defining small-intestinal carcinoid neoplasia. Ann. Surg. Oncol. 13, 253-262 (2006
105. Leja, J., et al. Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas. Mod. Pathol. 22, 261-272 (2009
106. Cui, T., et al. Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors. PLoS ONE 5, e16010 2010
107. Li, S. C., et al. Global microRNA profiling of well-differentiated small intestinal neuroendocrine tumors. Mod. Pathol. 26, 685-696 (2013
108. Kerr, S. E., et al. A 92 gene cancer classifier predicts the site of origin for neuroendocrine tumors. Mod. Pathol. 27, 44-54 (2014
109. Modlin, I. M., Kidd, M., Bodei, L., Drozdov, I., & Aslanian, H. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract. Am. J. Gastroenterol. 110, 1223-1232 (2015
110. Kidd, M., Drozdov, I., & Modlin, I. Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status. Endocr. Relat. Cancer 22, 561-575 (2015
111. Svejda, B., et al. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT. Cancer 117, 4141-4154 (2011
112. Li, H. J., Kapoor, A., Giel-Moloney, M., Rindi, G., & Leiter, A. B. Notch signaling differentially regulates the cell fate of early endocrine precursor cells and their maturing descendants in the mouse pancreas and intestine. Dev. Biol. 371, 156-169 (2012
113. Fendrich, V., et al. Snail and Sonic Hedgehog activation in neuroendocrine tumors of the ileum. Endocr. Relat. Cancer 14, 865-874 (2007
114. Shida, T., et al. Sonic Hedgehog-Gli1 signaling pathway might become an effective therapeutic target in gastrointestinal neuroendocrine carcinomas. Cancer Biol. Ther. 5, 1530-1538 (2006
115. Di Florio, A., et al. Src kinase activity coordinates cell adhesion and spreading with activation of mammalian target of rapamycin in pancreatic endocrine tumour cells. Endocr. Relat. Cancer 18, 541-554 (2011
116. von Wichert, G., et al. Insulin-like growth factor I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res. 60, 4573-4581 (2000
117. Besig, S., Voland, P., Baur, D. M., Perren, A., & Prinz, C. Vascular endothelial growth factors, angiogenesis, and survival in human ileal enterochromaffin cell carcinoids. Neuroendocrinology 90, 402-415 (2009
118. Wolin, E. M. The expanding role of somatostatin analogs in the management of neuroendocrine tumors. Gastrointest. Cancer Res. 5, 161-168 (2012
119. Oberg, K., et al. Consensus report on the use ofsomatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann. Oncol. 15, 966-973 (2004
120. Shah, T., et al. Epidermal growth factor receptor expression and activation in neuroendocrine tumours. J. Neuroendocrinol. 18, 355-360 (2006
121. Very, N. M., Kittilson, J. D., Klein, S. E., & Sheridan, M. A. Somatostatin inhibits basal and growth hormone-stimulated hepatic insulin-like growth factor I production. Mol. Cell. Endocrinol. 281, 19-26 (2008
122. Svejda, B., et al. Serotonin and the 5 HT7 receptor: a link between hepatocytes, IGF 1 and small intestinal neuroendocrine tumors. Cancer Sci. 104, 844-855 (2013
123. Porta, C., Paglino, C., & Mosca, A. Targeting PI3K/Akt/mTOR signaling in Cancer. Front. Oncol. 4, 64 (2014
124. Yang, Q., & Guan, K. L. Expanding mTOR signaling. Cell Res. 17, 666-681 (2007
125. Kasajima, A., et al. mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. Endocr. Relat. Cancer 18, 181-192 (2011
126. Larson, A. M., et al. Pancreatic neuroendocrine tumors in patients with tuberous sclerosis complex. Clin. Genet. 82, 558-563 (2012
127. Han, X., Ji, Y., Zhao, J., Xu, X., & Lou, W. Expression of PTEN and mTOR in pancreatic neuroendocrine tumors. Tumour Biol. 34, 2871-2879 (2013
128. Wang, L., Ignat, A., & Axiotis, C. A. Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms. Appl. Immunohistochem. Mol. Morphol. 10, 139-146 (2002
129. O-Toole, D., et al. Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors. Endocr. Relat. Cancer 17, 847-856 (2010
130. Yao, J. C., et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 514-523 (2011
131. Pavel, M. E., et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT 2): a randomised, placebo-controlled, phase 3 study. Lancet 378, 2005-2012 (2011
132. Yao, J. C., et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT 4): a randomised, placebo-controlled, phase 3 study. Lancet 387, 968-977 (2016
133. Zitzmann, K., et al. Compensatory activation of Akt in response to mTOR and Raf inhibitors- a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett. 295, 100-109 (2010
134. Moelling, K., Schad, K., Bosse, M., Zimmermann, S., & Schweneker, M. Regulation of Raf-Akt cross-talk. J. Biol. Chem. 277, 31099-31106 (2002
135. Zhu, J., Blenis, J., & Yuan, J. Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc. Natl Acad. Sci. USA 105, 6584-6589 (2008
136. Reusch, H. P., Zimmermann, S., Schaefer, M., Paul, M., & Moelling, K. Regulation of Raf by Akt controls growth and differentiation in vascular smooth muscle cells. J. Biol. Chem. 276, 33630-33637 (2001
137. Rozengurt, E., Soares, H. P., & Sinnet-Smith, J. Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance. Mol. Cancer Ther. 13, 2477-2488 (2014
138. US National Library of Science ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01628913 (2016
139. Salazar, R., et al. Phase II studies of BEZ235 in patients with advanced pancreatic neuroendocrine tumors (pNET) [abstract]. J. Clin. Oncol. 33 (Suppl.), 4102 (2015
140. Perren, A., et al. BRAF and endocrine tumors: mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors. Endocr. Relat. Cancer 11, 855-860 (2004
141. Karhoff, D., et al. Rap1/B Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target. Neuroendocrinology 85, 45-53 (2007
142. Wulbrand, U., et al. Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours. Eur. J. Clin. Invest. 28, 1038-1049 (1998
143. Nilsson, O., Wangberg, B., Theodorsson, E., Skottner, A., & Ahlman, H. Presence of IGF I in human midgut carcinoid tumours- an autocrine regulator of carcinoid tumour growth? Int. J. Cancer 51, 195-203 (1992
144. Samani, A. A., Yakar, S., LeRoith, D., & Brodt, P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr. Rev. 28, 20-47 (2007
145. Gloesenkamp, C., et al. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors. Int. J. Oncol. 40, 1659-1667 (2012
146. Reidy-Lagunes, D L., et al. A phase 2 study of the insulin-like growth factor 1 receptor inhibitor MK 0646 in patients with metastatic, well-differentiated neuroendocrine tumors. Cancer 118, 4795-4800 2012
147. Strosberg, J. R., et al. A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors. Endocr. Relat. Cancer 20, 383-390 (2013
148. Libutti, S. K. Therapy: blockade of IGF 1R not effective in neuroendocrine tumours. Nat. Rev. Endocrinol. 9, 389-390 (2013
149. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00781911 (2016
150. US National Library of Science. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01431547 (2015
151. Gilbert, J. A. et al. Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors. Endocr. Relat. Cancer 17, 623-636 (2010).
152. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00843531 (2015
153. US National Library of Science. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01172717 (2013
154. Olsson, A. K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. VEGF receptor signalling- in control of vascular function. Nat. Rev. Mol. Cell Biol. 7, 359-371 (2006
155. Bowen, K. A., et al. An analysis of trends and growth factor receptor expression of GI carcinoid tumors. J. Gastrointest. Surg. 13, 1773-1780 (2009
156. Kidd, M., et al. CTGF, intestinal stellate cells and carcinoid fibrogenesis. World J. Gastroenterol. 13, 5208-5216 (2007
157. Zhang, J., et al. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 109, 1478-1486 (2007
158. Yao, J. C., et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alfa 2b. J. Clin. Oncol. 26, 1316-1323 (2008
159. Chan, J. A., et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 30, 2963-2968 (2012
160. Castellano, D., et al Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: a phase II study of the Spanish Neuroendocrine Tumors Group (GETNE0801). J. Clin. Oncol. 49, 3780-3787 (2013
161. Phan, A. T., et al. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol. 16, 695-703 (2015
162. Raymond, E., et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 501-513 (2011
163. Zurita, A. J., et al. Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours. Br. J. Cancer 112, 1199-1205 (2015
164. Topalian, S. L., et al. Safety, activity, and immune correlates of anti PD 1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012
165. Khan, M. S., et al. Circulating tumor cells as prognostic markers in neuroendocrine tumors. J. Clin. Oncol. 31, 365-372 (2013
166. Modlin, I. M., et al. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection. Endocr. Relat. Cancer 21, 615-628 (2014
167. Modlin, I. M., Drozdov, I., & Kidd, M. The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood. PLoS ONE 8, e63364 2013
168. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00428220 (2015
169. US National Library of Science. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02315625 (2016